>
Alexion Pharmaceuticals Inc logo

ALXN - Alexion Pharmaceuticals Inc Share Price

$182.5 0.0  0.0%

Last Trade - 20/07/21

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £4.61bn
Position in Universe th / 7397
Bullish
Bearish
Unlock ALXN Revenue
Momentum
Relative Strength (%)
1m +4.65%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2,604 3,084 3,551 4,131 4,991 6,070 6,713 7,223 +18.4%
-73.4 +123.5 +32.6 +100.9 +97.0 -14.1 +46.6 +6.22
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AlexionPharmaceuticals, Inc. revenues increased 13% to $1.64B. Netincome increased 14% to $636M. Revenues reflect ULTOMIRISsegment increase of 56% to $346.9M, Strensiq segmentincrease of 15% to $197.5M. Net income benefited fromAcquisition-related costs decrease of 65% to $13.2M(expense), Amortization of purchased intangible assdecrease of 28% to $53.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ALXN
Graphical History

Revenue

ALXN Revenue Unlock ALXN Revenue

Net Income

ALXN Net Income Unlock ALXN Revenue

Normalised EPS

ALXN Normalised EPS Unlock ALXN Revenue

PE Ratio Range

ALXN PE Ratio Range Unlock ALXN Revenue

Dividend Yield Range

ALXN Dividend Yield Range Unlock ALXN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2022
31st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALXN EPS Forecasts Unlock ALXN Revenue
Profile Summary

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company’s marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 81
No. of Employees: 3,837
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange NASDAQ Global Select Market
Shares in Issue 221,675,313
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALXN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALXN
Upcoming Events for ALXN
Frequently Asked Questions for Alexion Pharmaceuticals Inc
What is the Alexion Pharmaceuticals Inc share price?

As of 20/07/21, shares in Alexion Pharmaceuticals Inc are trading at $182.5, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Alexion Pharmaceuticals Inc share price performed this year?

Shares in Alexion Pharmaceuticals Inc are currently trading at $182.5 and the price has moved by 66.61% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alexion Pharmaceuticals Inc price has moved by 41.62% over the past year.

What are the analyst and broker recommendations for Alexion Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Alexion Pharmaceuticals Inc, there are there are currently 1 "buy" , 13 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alexion Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Alexion Pharmaceuticals Inc next release its financial results?

Alexion Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Alexion Pharmaceuticals Inc dividend yield?

Alexion Pharmaceuticals Inc does not currently pay a dividend.

Does Alexion Pharmaceuticals Inc pay a dividend?

Alexion Pharmaceuticals Inc does not currently pay a dividend.

When does Alexion Pharmaceuticals Inc next pay dividends?

Alexion Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Alexion Pharmaceuticals Inc shares?

To buy shares in Alexion Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alexion Pharmaceuticals Inc?

Shares in Alexion Pharmaceuticals Inc are currently trading at $182.5, giving the company a market capitalisation of £n/a.

Where are Alexion Pharmaceuticals Inc shares listed? Where are Alexion Pharmaceuticals Inc shares listed?

Here are the trading details for Alexion Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALXN
What kind of share is Alexion Pharmaceuticals Inc?

We were not able to load our ranking data for Alexion Pharmaceuticals Inc

Is there a Alexion Pharmaceuticals Inc share price forecast 2022?

We were not able to load any forecast data for Alexion Pharmaceuticals Inc.

How can I tell whether the Alexion Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alexion Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 12.79%. At the current price of $182.5, shares in Alexion Pharmaceuticals Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alexion Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Alexion Pharmaceuticals Inc.

Who are the key directors of Alexion Pharmaceuticals Inc?

We were unable to find the directors for Alexion Pharmaceuticals Inc.

Who are the major shareholders of Alexion Pharmaceuticals Inc?

Here are the top five shareholders of Alexion Pharmaceuticals Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.19% (20.4m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.49% (12.2m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.53% (10.0m shares)
Farallon Capital Management, L.L.C. Hedge Fund
Percentage owned: 3.48% (7.71m shares)
Davidson Kempner Capital Management LP Hedge Fund
Percentage owned: 2.47% (5.47m shares)
Similar to ALXN
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.